Quick Answer
INTERPACE BIOSCIENCES, INC. reported Operating Income Loss of $4.08 million for the year ending 2025.
- INTERPACE BIOSCIENCES, INC. showed a decrease of -49.6% in Operating Income Loss from 2024 to 2025.
- This data is from INTERPACE BIOSCIENCES, INC.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), INTERPACE BIOSCIENCES, INC.'s Operating Income Loss has grown by 159.2%.
- Historical annual values: Fiscal year 2025: $4.08 million | Fiscal year 2024: $8.11 million | Fiscal year 2023: $3.96 million | Fiscal year 2022: -$3.62 million | Fiscal year 2021: -$6.34 million | Fiscal year 2020: -$26.07 million | Fiscal year 2019: -$26.44 million | Fiscal year 2018: -$12.12 million | Fiscal year 2017: -$6.29 million | Fiscal year 2016: -$6.44 million | Fiscal year 2015: -$40.41 million | Fiscal year 2014: -$17.83 million | Fiscal year 2013: -$1.44 million | Fiscal year 2012: -$25.23 million | Fiscal year 2011: -$4.70 million | Fiscal year 2010: -$6.90 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: